The immunoreactive patient: Rejection and autoimmune disease

Area of Science:

• Transplantation immunology
• Hepatology
• Immunosuppression therapy

Background:

• Graft failure due to rejection is a significant concern in organ transplantation.
• Optimizing immunosuppression is crucial for long-term graft survival.
• Understanding recurrence patterns of liver diseases post-transplantation is essential.

Purpose of the Study:

• To evaluate the effectiveness of current immunosuppression strategies in preventing graft failure.
• To investigate factors influencing graft rejection and recurrence of native liver diseases.
• To assess the impact of specific therapies on transplant outcomes.

Main Methods:

• Analysis of patient cohorts undergoing transplantation.
• Review of immunosuppression regimens and their efficacy.
• Assessment of disease recurrence and response to treatment.

Main Results:

• A subset of patients remains at risk of graft failure from rejection despite potent immunosuppression.
• Escalated immunosuppression shows limited efficacy in steroid-resistant chronic rejection.
• Interferon therapy for hepatitis C may increase rejection rates.
• Cyclosporine reduces primary biliary cirrhosis recurrence but not survival.
• Primary sclerosing cholangitis recurrence is unaffected by immunosuppression.
• Autoimmune hepatitis recurrence is generally responsive to corticosteroids.

Conclusions:

• Graft rejection remains a challenge, necessitating further research into effective management strategies.
• Specific therapeutic interventions have varied impacts on rejection and disease recurrence post-transplantation.
• Tailoring immunosuppression and managing comorbid conditions are critical for improving transplant outcomes.